OPU
IBER

Omni Partners US’s Ibere Pharmaceuticals IBER Stock Holding History

Omni Partners US’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$567K Sell
58,552
-15,591
-21% -$151K 0.03% 220
2021
Q2 		$717K Buy
+74,143
New +$721K 0.03% 188

Other funds holding IBER

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Omni Partners US's IBER Position: Q3 2021 in Review

Omni Partners US reduced its Ibere Pharmaceuticals (IBER) stake by 21% in Q3 2021, selling an estimated $151K and leaving 58,552 shares worth $567K. The position accounts for 0.03% of the portfolio, ranked #220.

Omni Partners US first reported a position in IBER in Q2 2021 and has held it in 2 quarters since. The position peaked at $717K in Q2 2021. 38 funds tracked by Wall St. Rank hold IBER as of Q3 2021.

  • Omni Partners US held 58,552 shares of Ibere Pharmaceuticals worth $567K as of Q3 2021.
  • Omni Partners US sold 15,591 Ibere Pharmaceuticals shares in Q3 2021, an estimated $151K.
  • Ibere Pharmaceuticals made up 0.03% of Omni Partners US's portfolio in Q3 2021, its #220 holding.
  • Omni Partners US first reported a position in Ibere Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • Omni Partners US's Ibere Pharmaceuticals position peaked at $717K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.